221 Main Street, Suite 1350
17 articles with Atomwise
Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB).
In a list of the most innovative companies in 2021, Fast Company has outlined 10 biotech companies that continue to revolutionize the drug-discovery landscape.
Atomwise, the leader in using artificial intelligence for small-molecule drug discovery, unveiled its growing portfolio of emerging joint venture companies with research programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders.
Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks
Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future.
The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications
Strategic collaboration to integrate AI technology, drug development expertise and ecosystem of partners for the commercialization of promising early-stage research
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules
Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas
Hansoh Pharma to innovate using artificial intelligence (AI) technology to generate first in-class and best in-class small molecules.
Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients
Atomwise Inc., a leader in artificial intelligence (AI) for drug discovery, and Atropos Therapeutics, Inc., a senescence platform discovery company, announced today that they will launch a joint venture company to discover and advance a pipeline of compounds for promising discovery targets for the treatment of cancer.
SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery
Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients
Atomwise and OncoStatyx Announce Joint Venture to Develop Small Molecule Inhibitors of Oncology Target KDM5B
Atomwise, Inc. announced the launch of a joint venture with OncoStatyx, LLC, an oncology focused preclinical stage biotechnology company based in Ohio.
Research Collaboration Between U-M and Atomwise to Accelerate Drug Discovery Using Innovative Artificial Intelligence Approach
Michigan Medicine researchers are Alan Smrcka, Ph.D., U-M Department of Pharmacology and Daniel Lawrence, Ph.D., Department of Internal Medicine, Cardiovascular Medicine
Atomwise and Enamine to Advance Pediatric Oncology With the World’s First and Largest Ten Billion Compound Virtual Screen
Atomwise, Enamine, and top university researchers collaborate to discover novel small molecules for the treatment of pediatric cancers using the power of AI and novel chemistry.
Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program
The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential new medicines.
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery
Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform
Atomwise and Charles River Laboratories Form a Strategic Alliance to Provide Premier Artificial Intelligence-Powered Drug Discovery Capabilities
Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery.